MX2009005071A - Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. - Google Patents

Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Info

Publication number
MX2009005071A
MX2009005071A MX2009005071A MX2009005071A MX2009005071A MX 2009005071 A MX2009005071 A MX 2009005071A MX 2009005071 A MX2009005071 A MX 2009005071A MX 2009005071 A MX2009005071 A MX 2009005071A MX 2009005071 A MX2009005071 A MX 2009005071A
Authority
MX
Mexico
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
pharmaceutically acceptable
ksp
Prior art date
Application number
MX2009005071A
Other languages
English (en)
Inventor
Paul A Renhowe
Yi Xia
Kris G Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005071A publication Critical patent/MX2009005071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se dan a conocer nuevos compuestos de pirazol y triazol sustituidos de la fórmula (I), y sales farmacéuticamente aceptables, ésteres o pro-fármacos de los mismos, composiciones de los derivados junto con vehículos farmacéuticamente aceptables, y usos de los mismos: (ver fórmula (I)).
MX2009005071A 2006-11-13 2007-11-08 Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. MX2009005071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13
PCT/US2007/084154 WO2008063912A1 (en) 2006-11-13 2007-11-08 Substituted pyrazole and triazole compounds as ksp inhibitors

Publications (1)

Publication Number Publication Date
MX2009005071A true MX2009005071A (es) 2009-05-25

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005071A MX2009005071A (es) 2006-11-13 2007-11-08 Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Country Status (32)

Country Link
US (2) US8129358B2 (es)
EP (1) EP2091926B1 (es)
JP (1) JP5264755B2 (es)
KR (1) KR20090081020A (es)
CN (1) CN101558049B (es)
AR (1) AR063805A1 (es)
AU (1) AU2007323998B2 (es)
BR (1) BRPI0719002A2 (es)
CA (1) CA2668661A1 (es)
CL (1) CL2007003272A1 (es)
CO (1) CO6382171A2 (es)
CR (1) CR10787A (es)
DO (1) DOP2009000106A (es)
EA (1) EA017748B1 (es)
EC (1) ECSP099326A (es)
ES (1) ES2557478T3 (es)
GE (1) GEP20125389B (es)
GT (1) GT200900122A (es)
HN (1) HN2009000968A (es)
IL (1) IL198471A0 (es)
MA (1) MA30959B1 (es)
MX (1) MX2009005071A (es)
NI (1) NI200900084A (es)
NO (1) NO20092226L (es)
NZ (1) NZ576640A (es)
PE (1) PE20081169A1 (es)
SM (1) SMP200900045B (es)
TN (1) TN2009000178A1 (es)
TW (1) TW200831480A (es)
UA (1) UA97256C2 (es)
WO (1) WO2008063912A1 (es)
ZA (1) ZA200902940B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
BRPI0806264A2 (pt) * 2007-01-05 2011-08-30 Novartis Ag derivados ciclizados como inibidores de eg-5
JP2013525290A (ja) * 2010-04-15 2013-06-20 ノバルティス アーゲー Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
CA2892919A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CN105793240B (zh) 2013-12-04 2018-05-18 默沙东公司 用于制备逆转录酶抑制剂的方法
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2017097927A1 (en) * 2015-12-11 2017-06-15 Syngenta Participations Ag Pesticidally active 1,2,4-triazole derivatives
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
CA2369549A1 (en) 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
CA2388646C (en) 1999-10-27 2009-01-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
EP1458726B1 (en) 2001-12-06 2009-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸***キネシン阻害剤
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
AU2002357043B2 (en) 2001-12-06 2008-04-24 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1465896A4 (en) 2001-12-06 2006-01-11 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
US20040259936A1 (en) * 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2003223786A1 (en) 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
WO2003099211A2 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
US7348440B2 (en) 2002-06-14 2008-03-25 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2486215A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸***キネシン結合部位
AU2003252025A1 (en) 2002-07-17 2004-02-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004100873A2 (en) 2003-05-07 2004-11-25 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004103282A2 (en) 2003-05-15 2004-12-02 Cytokinetics, Inc. Compounds, compositions and methods
DE602005012069D1 (de) * 2004-04-06 2009-02-12 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
PT1753723E (pt) 2004-05-21 2008-11-19 Novartis Vaccines & Diagnostic Derivados de quinolina substituída como inibidores de quinesina mitótica
BRPI0510929A (pt) * 2004-06-18 2007-07-17 Chiron Corp derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
CA2584979A1 (en) 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
MY147188A (en) * 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
EP2091926A1 (en) 2009-08-26
CN101558049B (zh) 2012-08-15
WO2008063912A1 (en) 2008-05-29
SMAP200900045A (it) 2009-07-14
UA97256C2 (ru) 2012-01-25
PE20081169A1 (es) 2008-09-24
NZ576640A (en) 2011-10-28
ZA200902940B (en) 2010-05-26
GT200900122A (es) 2011-09-14
GEP20125389B (en) 2012-01-25
CO6382171A2 (es) 2012-02-15
NI200900084A (es) 2010-01-29
JP2010509365A (ja) 2010-03-25
CR10787A (es) 2009-07-02
NO20092226L (no) 2009-08-12
ECSP099326A (es) 2009-06-30
US8129358B2 (en) 2012-03-06
ES2557478T3 (es) 2016-01-26
US20080200462A1 (en) 2008-08-21
AU2007323998A1 (en) 2008-05-29
CL2007003272A1 (es) 2008-03-24
BRPI0719002A2 (pt) 2013-12-17
IL198471A0 (en) 2010-02-17
US7902240B2 (en) 2011-03-08
CN101558049A (zh) 2009-10-14
JP5264755B2 (ja) 2013-08-14
DOP2009000106A (es) 2009-05-31
AR063805A1 (es) 2009-02-18
HN2009000968A (es) 2011-10-25
TW200831480A (en) 2008-08-01
SMP200900045B (it) 2010-03-01
EP2091926B1 (en) 2015-10-21
EA200900631A1 (ru) 2009-12-30
AU2007323998B2 (en) 2011-09-22
CA2668661A1 (en) 2008-05-29
EA017748B1 (ru) 2013-02-28
KR20090081020A (ko) 2009-07-27
US20100034813A1 (en) 2010-02-11
TN2009000178A1 (en) 2010-10-18
MA30959B1 (fr) 2009-12-01

Similar Documents

Publication Publication Date Title
MX2009005071A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
TW200612958A (en) Substituted imidazole derivatives
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
MX2007004699A (es) Derivados de indol y bencimidazol.
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
SI1753723T1 (sl) Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
WO2007117465A3 (en) Indazole compounds
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
IL193620A0 (en) Spiroindolinone derivatives
MX2009008506A (es) Derivados del pirazol como inhibidores de 11-b-hsd1.
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
MX2010009739A (es) Inhibidores de cinasa pim y metodos para su uso.
MX2012003982A (es) Pirrolidinas n-substituidas.
IL205354A0 (en) Spiroindolinone derivatives
MY153985A (en) Aminotriazole derivatives as alx agonists
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
WO2007084728A3 (en) 2-imino-benzimidazoles
TNSN08191A1 (en) Kinase inhibitors
TNSN08369A1 (en) Benzimidazole derivatives
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MY156955A (en) Antifungal agents
MX2009013003A (es) Derivados de piperidina-amida.
MX2009003793A (es) Inhibidores de cinasa.
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.

Legal Events

Date Code Title Description
FG Grant or registration